Meridian Wealth Management’s DiaMedica Therapeutics DMAC Stock Holding History

Meridian Wealth Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Sell	43,600 -5,041	-10%	-$31K	0.01%	669
2026 Q1	$329K	Sell	48,641 -2,000	-4%	-$15.8K	0.01%	625
2025 Q4	$403K	Sell	50,641 -1,025	-2%	-$7.67K	0.01%	549
2025 Q3	$355K	Buy	51,666 +24,350	+89%	+$132K	0.01%	552
2025 Q2	$107K	Sell	27,316 -1,500	-5%	-$5.85K	﹤0.01%	655
2025 Q1	$109K	Buy	28,816 +1,600	+6%	+$9.15K	0.01%	605
2024 Q4	$148K	Buy	+27,216	New	+$128K	0.01%	610

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Meridian Wealth Management's DMAC Position: Q2 2026 in Review

Meridian Wealth Management reduced its DiaMedica Therapeutics (DMAC) stake by 10% in Q2 2026, selling an estimated $31K and leaving 43,600 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #669.

Meridian Wealth Management first reported a position in DMAC in Q4 2024 and has held it in 7 quarters since. The position peaked at $403K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Meridian Wealth Management held 43,600 shares of DiaMedica Therapeutics worth $307K as of Q2 2026.
Meridian Wealth Management sold 5,041 DiaMedica Therapeutics shares in Q2 2026, an estimated $31K.
DiaMedica Therapeutics made up 0.01% of Meridian Wealth Management's portfolio in Q2 2026, its #669 holding.
Meridian Wealth Management first reported a position in DiaMedica Therapeutics in Q4 2024 and has held it in 7 quarters since.
Meridian Wealth Management's DiaMedica Therapeutics position peaked at $403K in Q4 2025.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Meridian Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.